Gilead’s HIV Products Target Of Subpoena From DoJ
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing and educational programs are the focus of inquiry from the U.S. Attorney’s Office in San Francisco, but the probe does not include the recently approved combination Atripla.